SCHEMBL22978627

SCHEMBL22978627

CCOc1cc(CBr)nn1C

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24510005 0.81 KDM4E (0.33)
SCHEMBL21607865 0.81 NOTUM (0.37) BCHE
SCHEMBL26970966 0.81 BCHE (0.32) BCHE
SCHEMBL21597038 0.79 ATM (0.36) BCHE
SCHEMBL10715626 0.75 KDM1A (0.37)
SCHEMBL22978634 0.73 ALDH1A1 (0.31)
SCHEMBL24685885 0.73 ALDH1A1 (0.33)
SCHEMBL21607979 0.73 LMNA (0.35)
SCHEMBL25786587 0.71 BCHE (0.33) BCHE
SCHEMBL1279668 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4010334-A1 HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS Novartis AG (CH) 2022-06-15 EP disclosed
WO-2021026672-A1 HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS NOVARTIS AG (CH) 2021-02-18 WO disclosed
WO-2021028806-A1 HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS NOVARTIS AG (CH) 2021-02-18 WO disclosed